
The Leukemia & Lymphoma Society (LLS) and Celator Pharmaceuticals, Inc announced a significant expansion of their partnership to support clinical development of Celator's CPX-351 (cytarabine:daunorubicin) liposome injection for treatment of adults with acute myeloid leukemia (AML).


















































































































































































































